Plinabulin

Generic Name: Plinabulin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀N_₄O_₂

CAS Number: 714272-27-2

Unique Ingredient Identifier: 986FY7F8XR

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Plinabulin

First Posted Date: 2021-11-23

Last Posted Date: 2024-08-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT05130827

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1

Active, not recruiting

Conditions: Clinical Stage IV Merkel Cell Carcinoma AJCC v8
Advanced Bladder Carcinoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma

Interventions: Biological: Atezolizumab
Drug: Avelumab
Biological: Durvalumab
Biological: Nivolumab
Biological: Pembrolizumab
Drug: Plinabulin
Radiation: Radiation Therapy

First Posted Date: 2021-05-26

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT04902040

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Phase 2

Completed

Conditions: Chemotherapy-induced Neutropenia

Interventions: Drug: Plinabulin
Drug: Pegfilgrastim

First Posted Date: 2020-04-15

Last Posted Date: 2024-05-16

Lead Sponsor: BeyondSpring Pharmaceuticals Inc.

Target Recruit Count: 55

Registration Number: NCT04345900

Locations: 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇺🇸
Emad Ibrahim, MD, Inc., Redlands, California, United States
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Harbin, China

and more 16 locations

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Phase 2

Completed

Conditions: Chemotherapy-induced Neutropenia

Interventions: Drug: Plinabulin
Drug: Pegfilgrastim
Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

First Posted Date: 2020-01-14

Last Posted Date: 2020-01-18

Lead Sponsor: BeyondSpring Pharmaceuticals Inc.

Target Recruit Count: 115

Registration Number: NCT04227990

Locations: 🇨🇳
Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China
🇨🇳
Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China
🇨🇳
China-Japan Union Hospital of Jilin University Tumor department of Hematology, Changchun, Jilin, China

and more 8 locations

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
SCLC

Interventions: Drug: Nivolumab
Drug: Plinabulin
Drug: Ipilimumab

First Posted Date: 2018-07-03

Last Posted Date: 2024-11-12

Lead Sponsor: Salma Sabbour

Target Recruit Count: 39

Registration Number: NCT03575793

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 5 locations

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Phase 3

Active, not recruiting

Conditions: Chemotherapy-induced Neutropenia

Interventions: Drug: Pegfilgrastim
Drug: Plinabulin
Other: D5W Placebo
Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

First Posted Date: 2017-09-27

Last Posted Date: 2021-01-15

Lead Sponsor: BeyondSpring Pharmaceuticals Inc.

Target Recruit Count: 221

Registration Number: NCT03294577

Locations: 🇺🇦
Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department, Dnepropetrovsk, Ukraine
🇺🇦
Prykarpatskiy Regional Oncological Center, Ivano-Frankivs'k, Ukraine
🇺🇦
V.T. Zaycev Institute, Kharkiv, Ukraine

and more 17 locations

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Phase 3

Completed

Conditions: Chemotherapy-induced Neutropenia

Interventions: Drug: Pegfilgrastim
Drug: Plinabulin
Other: D5W Placebo
Other: Saline Placebo

First Posted Date: 2017-04-06

Last Posted Date: 2024-08-29

Lead Sponsor: BeyondSpring Pharmaceuticals Inc.

Target Recruit Count: 105

Registration Number: NCT03102606

Locations: 🇺🇸
Stanford University School of Medicine - Cancer Institute, Stanford, California, United States
🇺🇸
Hematology/Oncology of the North Shore, Skokie, Illinois, United States
🇨🇳
Heilongjiang Cancer Hospital, Harbin, Heilongjiang, China

and more 15 locations

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: ALK Gene Translocation
EGFR Activating Mutation
ROS1 Gene Translocation
Stage IV Non-Small Cell Lung Cancer AJCC v7
Recurrent Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Interventions: Biological: Nivolumab
Drug: Plinabulin

First Posted Date: 2016-07-27

Last Posted Date: 2019-03-04

Lead Sponsor: University of Washington

Target Recruit Count: 5

Registration Number: NCT02846792

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy